4 April 2016 ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer’s Disease
16 February 2016 Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum
29 January 2016 Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
29 December 2015 Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors
16 December 2015 ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer’s Disease